Results 41 to 50 of about 1,056 (174)

A Case of Galactorrhea and Hyperprolactinemia Following Nemolizumab Administration. [PDF]

Pediatr Int
Sakai H, Oi T, Yoshioka K, Igarashi T.
europepmc   +2 more sources

Role of Nemolizumab and Omalizumab in management of atopic dermatitis: A review [PDF]

, 2021
BackgroundNemolizumab (CIM331) is a monoclonal antibody that binds the IL-31 receptor α component. This inhibits IL-31 from acting on neurons that constrains the initialization of the sense of pruritus in cases of atopic dermatitis.AimsTo summarize the ...
Yousef Ali H Alaenzi; Aseer central Hospital, Abha , Saudi Arabia, Mohammed Abdulhafith R Alotaibi; Aseer central Hospital, Abha , Saudi Arabia, Sultan Makki M Alsharef; Aseer central Hospital, Abha , Saudi Arabia, Yousef Hussain J Alharthi; Aseer central Hospital, Abha , Saudi Arabia, Ibrahim Mahmoud H Ajwah; King Salman Armed Forced Hospital, Tabuk, Saudi Arabia, Ahmed Bakheet N Alharbi; King Salman Armed Forced Hospital, Tabuk, Saudi Arabia, Shifa Sameer A Nagadi; Dammam medical city, Dammam, Saudi Arabia, Maram Salim S Algrani; University of Tabuk, Saudi Arabia, Ali Abdulrahman A Alshehri; Aseer central Hospital, Abha , Saudi Arabia, Rayyan Fahad H Altemani; Aseer central Hospital, Abha , Saudi Arabia, Muneera Saeed F Alhayan; Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia, Omnia Abdulmonum A Alali; Aseer central Hospital, Abha , Saudi Arabia, Shumoukh Saleh F AlAfnan; University of Hail, Saudi Arabia, Ahmed Saad A Albalawi; Aseer central Hospital, Abha , Saudi Arabia, Zahra Shaker H Al-kalaif; Hera General Hospital, Makkah, Saudi Arabia   +14 more
core  

Single-cell profiling of prurigo nodularis demonstrates immune-stromal crosstalk driving profibrotic responses and reversal with nemolizumab [PDF]

, 2023
BACKGROUND: Prurigo nodularis (PN) is a chronic neuroimmune skin disease characterized by bilaterally distributed pruritic hyperkeratotic nodules on extremities and trunk.
Johann E. Gudjonsson, J. Michelle Kahlenberg, Nakamura, Mio, Julia, Valerie, Matthew T. Patrick, Van Delm, Wouter, Feiyang Ma, Paul Harms, Mehrnaz Gharaee-Kermani, Harms, Paul, Grace Hile, Gudjonsson, Johann E, Olesya Plazyo, Mio Nakamura, Ma, Feiyang, Tsoi, Lam C, Lazzari, Anne, Billi, Allison C, Gharaee-Kermani, Mehrnaz, Allison C. Billi, Modlin, Robert L, Chaskar, Prasad, Plazyo, Olesya, Anne Lazzari, Christophe Piketty, Xing, Xianying, Wouter Van Delm, Lam C. Tsoi, Krishnaswamy, Jayendra Kumar, Xianying Xing, Emanual Maverakis, Robert L. Modlin, Piketty, Christophe, Prasad Chaskar, Patrick, Matthew T, Valerie Julia, Maverakis, Emanual, Hile, Grace, Kahlenberg, J Michelle, Jayendra Kumar Krishnaswamy   +39 more
core   +1 more source

Nemolizumab for chronic pruritus beyond atopic dermatitis and prurigo nodularis: a systematic review and synthesis of emerging evidence

Journal of Dermatological Treatment
Background Nemolizumab, an anti-IL-31 receptor A antibody, is licensed for atopic dermatitis and prurigo nodularis; its role in other chronic pruritus (CP) syndromes is uncertain.Objective To synthesize efficacy, safety and strength of evidence for ...
Mohammed Shanshal, Aarthy Uthayakumar
doaj   +1 more source

Interleukin-31 as a Clinical Target for Pruritus Treatment

Frontiers in Medicine, 2021
In recent years, the published literature has suggested the key involvement of the cytokine interleukin-31 (IL-31) in the symptomatology of pruritus, and both IL-31 and its receptor have become potential therapeutic targets for a range of pruritic ...
Kenji Kabashima, Hiroyuki Irie
doaj   +1 more source

Validation of the Peak Pruritus Numerical Rating Scale as a Patient-Reported Outcome Measure in Prurigo Nodularis

Dermatology and Therapy, 2023
Introduction Validated patient report tools for quantifying patient experiences of itch in prurigo nodularis (PN) are limited. This study aimed to evaluate the validity of the 11-point peak pruritus numerical rating scale (PP NRS) as a single-item ...
Shawn G. Kwatra, Danielle Rodriguez, Carla Dias-Barbosa, Ismail Budhiarso, Fatoumata Fofana, Margaret Vernon, Sylvie Gabriel, Christophe Piketty, Jorge Puelles   +8 more
doaj   +1 more source

Trial of Nemolizumab and Topical Agents for Atopic Dermatitis with Pruritus

New England Journal of Medicine, 2020
Nemolizumab is a subcutaneously administered humanized monoclonal antibody against interleukin-31 receptor A, which is involved in pruritus and inflammation in atopic dermatitis. In phase 2 studies, nemolizumab lessened the severity of atopic dermatitis.In a 16-week, double-blind, phase 3 trial, we randomly assigned Japanese patients with atopic ...
Kenji, Kabashima, Takayo, Matsumura, Hiroshi, Komazaki, Makoto, Kawashima   +3 more
openaire   +2 more sources

Optimal Use of Jak Inhibitors and Biologics for Atopic Dermatitis on the Basis of the Current Evidence

JID Innovations, 2023
Recently, Jak inhibitors such as baricitinib, upadacitinib, and abrocitinib were approved for the treatment of atopic dermatitis (AD) in addition to biologics, including dupilumab, tralokinumab, and nemolizumab. The increase in treatment options can be a
Masahiro Kamata, Yayoi Tada
doaj   +1 more source

When Treatment Meets Natural History: Understanding Early Dermatitis‐Related Adverse Events in Systemic Atopic Dermatitis Trials

JEADV Clinical Practice, EarlyView.
ABSTRACT Biologics and Janus kinase (JAK) inhibitors have transformed the management of atopic dermatitis (AD), yet some patients experience early worsening of disease activity during treatment initiation. In clinical trials, these events are typically recorded as treatment‐emergent adverse events (TEAEs), most commonly coded as “atopic dermatitis”. We
Diego Ruiz Dasilva, Alondra Soto‐Gonzalez, Haya Alkiswani, Graham H. Litchman, Harrison Nguyen, Gil Yosipovitch, Firas George Hougeir, Matthew Zirwas, David Cotter, Brad Glick, E. James Song, Christopher G. Bunick, Neal Bhatia, Adam Friedman, Leon Kircik, Mona Shahriari, Peter Lio, James Del Rosso   +17 more
wiley   +1 more source

Nemolizumab is associated with a rapid improvement in atopic dermatitis signs and symptoms: subpopulation (EASI ≥ 16) analysis of randomized phase 2B study

, 2021
© 2021 Galderma SA. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology.
Pinter, A., Chaouche, K., J.M. Armstrong, C. Piketty, J.‐D. Bouaziz, Murrell, D. F., J.I. Silverberg, A. Wollenberg, Lynde, C., Wollenberg, A., Armstrong, J. M., V. Laquer, C. Lynde, S. Alpizar, F. Ahmad, A. Pinter, Alpizar, S., Silverberg, J. I., K. Chaouche, Bouaziz, J. D., Piketty, C., Ahmad, F., Alavi, A., A. Alavi, D.F. Murrell, Laquer, V.   +25 more
core   +1 more source